Fritextsökning
Artiklar per år
Innehållstyper
-
Samuel Lagercrantz: “Companies that do this successfully will take the lead”
The development of new medicines and medical technologies should not focus too narrowly on prolonging life. It is equally important to develop treatments that relieve pain or eliminate painful symptoms, writes Samuel Lagercrantz in an editorial.
-
Omvänt förvärv ska ta Flerie till börsen – ”Viktigt steg i bolagets plan”
Läkemedelsinvesteraren Flerie Invest tar en genväg till börsen genom ett omvänt förvärv av forskningsbolaget Index Pharmaceuticals.
-
Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed
Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.
-
Ny finansiering ska ta Linköpingsbolagets sensorsystem vidare
Linköpingsbolaget Argus Eye, som utvecklar sensorsystem för biologiska läkemedel, har tagit in 32,5 miljoner kronor i en finansieringsrunda.
-
Carl Borrebaeck – professor and serial entrepreneur with a taste for speed
Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borrebaeck, Professor of Immunotechnology at Lund, is not yet satisfied. “We have a new, potentially
-
Forskaren in Hagastaden now inagurated
The real estate company Vectura's life science center in Hagastaden, Forskaren, is now inaugurated. The opening was attended by people from the industry, politicians and royalty.
-
Ancient DNA provides new insights – “The immune system lost its job”
Ancient bone remains from our ancestors have provided new insights into the prevalence of multiple sclerosis. By looking back in time, researchers can provide a possible explanation for why the disease is more prevalent in northern Europe.
-
Yxan går hos läkemedelsjätte – över 2 000 jobb ska bort
Bristol Myers Squibb planerar stora neddragningar. Omkring 2 200 av bolagets anställda väntas få gå när läkemedelsjätten ska skära i kostnaderna.
-
Forskningscenter stoppas på grund av brister – ”Väldigt allvarligt”
Forskning som bedrivs utan tillstånd. Bristande kvalitetssäkring. Personuppgifter som hanteras felaktigt. Kritiken mot arbetet på Center for Bionics and Pain Research (CBPR) i Göteborg är så allvarlig att forskningsplattformen nu läggs på is.
-
List: The coolest names in biotech
Hairy beasts, volcanic material and space strolling stand out on a US list of the best biotech company names, and on a list of the coolest names for pharmaceuticals, a Swedish, or at least Swedish-British, drug came out on top.
-
Hon är ny på Gradientech
Diagnostikbolaget Gradientech har rekryterat AnnaLotta Schiller Vestergren till tjänsten som Chief Commercial Officer.
-
The Covid pandemic accelerated the development of cancer vaccine
The Covid pandemic gave a major boost to the vaccine field. The Danish biotech company Expres2ion Biotechnologies, which is developing a vaccine against breast cancer, testifies to this.
-
Coronapandemin påskyndade utveckling av cancervaccin
Coronapandemin gav ett stort uppsving för vaccinfältet. Det vittnar danska biotechbolaget Expres2ion Biotechnologies om, som utvecklar ett vaccin mot bröstcancer.
-
Beta-blockers are often given unnecessarily, a study finds – “This will affect future practice”
Patients who have suffered a minor heart attack do not benefit from beta-blockers, according to a major new study that may change guidelines for cardiac care.
-
Recipharm divests five Swedish plants
Swedish contract manufacturer Recipharm is selling its facilities in Solna, Strängnäs, Höganäs, Karlskoga and Uppsala OTC Development to US private equity company Blue Wolf Capital Partners.
-
Betablockerare ges ofta i onödan enligt stor studie – ”Kommer påverka framtida praxis”
Patienter som drabbats av en mindre hjärtinfarkt har ingen nytta av betablockerare, enligt en ny stor studie som kan komma att ändra riktlinjer för hjärtsjukvård.
-
The life science strategy – what the industry wants
The process of updating the national life science strategy has begun at the government’s life science office. According to industry stakeholders, Sweden’s competitiveness, the accessibility of health data and the integration of innovation in healthcare are some of the points that are essential to review.
-
”We need compatibility“
Penilla Gunther, founder of Fokus Patient and chair of the European Patient Safety Foundation, hopes that the forthcoming life science strategy will focus on efficient and secure management of patient data and equal access to medicines.
-
Behandling av prostatacancer får positivt EU-utlåtande
Prostataläkemedlet Xtandi har nu fått ett positivt utlåtande i EU av den europeiska läkemedelsmyndigheten EMA:s rådgivande grupp CHMP.
-
62-åring fick njure från gris i unik transplantation – "Återhämtar sig bra"
Amerikanska kirurger har genomfört den första transplantationen av en njure från en genmodifierad gris till en människa med njursjukdom.
-
Specific proposals and targets top the universities’ desired priorities
What are the universities’ expectations for the update of the national life science strategy? Life Science Sweden posed the question to representatives from Karolinska Institutet and Sahlgrenska Academy.
-
“Life science is important on a personal level”
From the High Coast to the Government Offices. Jeanette Edblad is a native of Ångermanland, and since September last year, she has been Head and Coordinator of the Government’s Life Science Office.
-
Samuel Lagercrantz: ”Will the Swedish life science strategy be updated with precision?”
What will the Swedish government focus on in the life science strategy that is being updated? And what should be prioritized in the strategy? Life Science Sweden's editor-in-chief Samuel Lagercrantz highlights three areas.
-
“What is important is to create an overview and understanding from different perspectives”
Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diagnostics of the Future event.
BREAKING